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The healthy adult heart has a low turnover of cardiac myocytes. The renewal capacity,
however, is augmented after cardiac injury. Participants in cardiac regeneration include
cardiac myocytes themselves, cardiac progenitor cells, and peripheral stem cells,
particularly from the bone marrow compartment. Cardiac progenitor cells and bone
marrow stem cells are augmented after cardiac injury, migrate to the myocardium, and
support regeneration. Depletion studies of these populations have demonstrated their
necessary role in cardiac repair. However, the potential of these cells to completely
regenerate the heart is limited. Efforts are now being focused on ways to augment these
natural pathways to improve cardiac healing, primarily after ischemic injury but in other
cardiac pathologies as well. Cell and gene therapy or pharmacological interventions are
proposed mechanisms. Cell therapy has demonstrated modest results and has passed
into clinical trials. However, the beneficial effects of cell therapy have primarily been their
ability to produce paracrine effects on the cardiac tissue and recruit endogenous stem
cell populations as opposed to direct cardiac regeneration. Gene therapy efforts have
focused on prolonging or reactivating natural signaling pathways. Positive results have
been demonstrated to activate the endogenous stem cell populations and are currently
being tested in clinical trials. A potential new avenue may be to refine pharmacological
treatments that are currently in place in the clinic. Evidence is mounting that drugs such
as statins or beta blockers may alter endogenous stem cell activity. Understanding the
effects of these drugs on stem cell repair while keeping in mind their primary function may
strike a balance in myocardial healing. To maximize endogenous cardiac regeneration,
a combination of these approaches could ameliorate the overall repair process to
incorporate the participation of multiple cellular players.
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Introduction
Despite the significant research effort that has gone into improving therapeutics and interventions
for coronary heart disease, it still remains a great societal, economic and clinical burden throughout
the world. In particular, myocardial infarction is attributable tomore than half of the cardiovascular
disease related mortality in the industrialized world (Go et al., 2014). The coronary occlusion in a
myocardial infarct results in significant cardiac cell damage and death. Current therapies are able
to attenuate symptoms and prolong life. However, an intervention has not yet been developed that
can replace or regenerate the damaged myocardium after an infarct. This is due in part to the
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absence of understanding and the potential of how the heart
tissue can be repaired or regenerated.
Evidence has accumulated over the past 15 years to
demonstrate that there is some amount of cardiac turnover,
both in healthy and injured tissue. Particular interest has
focused on cardiac regeneration after ischemic events due to
the large amount of myocyte death, but reports also describe
cardiac proliferation in models of cardiac pressure overload
and idiopathic dilated cardiomyopathy (Kajstura et al., 1998;
Urbanek et al., 2003). Cardiac cell proliferation is highest in
youth, reducing with increased age (Rumyantsev and Borisov,
1987; Mollova et al., 2013; Naqvi et al., 2014). In an average
healthy adult, the cardiomyocyte turnover rate is controversial
with reports predicting annual turnover rates ranging anywhere
from 0.3% to more than 50% (Bergmann et al., 2009; Kajstura
et al., 2010; Bergmann and Jovinge, 2014). Methods have
been questioned in studies where turnover is on the higher
end (Laflamme and Murry, 2011). Cardiomyocyte renewal is
augmented in cardiac pathological settings such as myocardial
infarction and heart failure (Rumyantsev and Borisov, 1987;
Kajstura et al., 1998; Beltrami et al., 2001). Due to these evidences,
it appears that the heart has some capacity for renewal though
it is limited and unable to compensate for significant cardiac
damage. It has been proposed that evolutionarymechanisms have
limited pathways of cardiac regeneration to protect the heart
from developing cancer (Penn, 2010). In fact, primary cardiac
tumors are extremely rare, representing only 0.3–0.7% of all
cardiac tumors (Leja et al., 2011). This endogenous capability
to regenerate does provoke a potential target for cardiac
therapies however. Reports demonstrate multiple cellular players
participating in endogenous cardiac regeneration (Figure 1).
The exact contribution of each cell type remains a topic of
controversy in the cardiac regenerative medicine field. Focusing
the repair potential to just one cell type may actually limit the
therapeutic opportunities. Instead it is likely that provoking each
of these players could provide an orchestrated andmore complete
regeneration.
Participants in Cardiac Regeneration
Cardiac Myocytes
Amputation studies in zebrafish and neonatal mice brought
to light the potential for cardiac regeneration by cardiac
myocytes themselves (Poss et al., 2002; Porrello et al., 2011). The
mechanisms proposed include the activation of cardiogenesis and
cell cycle genes and dedifferentiation (Jopling et al., 2010; Kikuchi
et al., 2010; Porrello et al., 2011; Mahmoud et al., 2013). However,
this capacity for complete regeneration in the mouse is lost by 1
week of age (Porrello et al., 2011). Studies are incongruous on
whether cardiac myocyte proliferation continues into adult life
(Walsh et al., 2010; Senyo et al., 2013). It does appear likely that
myocardial injury can induce to some extent pre-existing cardiac
myocyte renewal (Senyo et al., 2013).
Cardiac Progenitor Cells
Cardiac progenitor cells (CPC) are an adult stem cell population
residing in the heart. These cells have been identified by a number
of markers including c-kit, sca-1, Isl1, Wilms tumor 1, and the
ability to form cardiospheres in vitro (Beltrami et al., 2003;
Genead et al., 2010; Smart et al., 2011; Hsiao et al., 2014; Uchida
et al., 2013). It is evident that after a cardiac injury these cell
types proliferate and increase in number (Fransioli et al., 2008;
Smart et al., 2011; Uchida et al., 2013). It has even been suggested
that these cells are indispensable for cardiac regeneration (Ellison
et al., 2013). Disagreement exists on the exact differentiation
capabilities of these cells in vivo, particularly with the c-kit+ CPC
population. Research consistently reports the ability of the cells to
differentiate into an endothelial cell lineage but their contribution
to cardiac myocytes has been questioned (Hsieh et al., 2007;
Fransioli et al., 2008; Jesty et al., 2012). Ellison et al. found that
c-kit+ CPC significantly contribute to de novo cardiac myocyte
generation; whereas van Berlo et al. reported that differentiation
of c-kit+ cells to cardiac myocytes is negligible (Ellison et al.,
2013; Van Berlo et al., 2014). This discrepancy may in part be
due to the different transgenic mouse lines used between the
two studies. A study with the same mouse line used in the
Ellison study demonstrated that of the c-kit+ cells identified
by immunofluorescence, only 32% of the cells were positive
for fluorescent protein driven by the c-kit promoter (Fransioli
et al., 2008). This suggests that the results of the Ellison study
may potentially underestimate the involvement of c-kit+ cells.
Regardless of these issues, it is evident that CPC are responsive
to cardiac injury and differentiate into endothelial cells, aiding
in increased vessel density, a mechanism correlated to improved
cardiac function (Kim et al., 2014).
Peripheral Stem Cells
The bone marrow is a reservoir for multiple populations of adult
stem cells including, but not limited to, endothelial progenitor
cells (EPC), c-kit+ stem cells, very small embryonic like stem
cells, mesenchymal stem cells (MSC), and hematopoietic stem
cells. Bone marrow cells are mobilized into the peripheral
blood after cardiac injury and are recruited to the myocardium
(Mouquet et al., 2005; Finan et al., 2012). The recruitment of
bone marrow cells is associated with cardiac repair and along the
same lines, in studies where the bone marrow stem cells response
is attenuated, reduced accumulation of bone marrow cells is
associated with worse outcomes (Fazel, 2006; Sopko et al., 2010;
Finan et al., 2013; Gong et al., 2014). Bone marrow stem cells can
incorporate into the vasculature, differentiate into endothelial
cells, and participate in vascular remodeling (Finan et al., 2013;
Wu et al., 2015). Studies of gender mismatched bone marrow and
heart transplant patients demonstrated that bone marrow cells
have the capacity to differentiate into cardiac myocytes (Quaini
et al., 2002; Deb et al., 2003). However, a recent study suggests
that bone marrow cells do not directly differentiate into cardiac
myocytes and instead suggests their fusion with existing cardiac
myocytes (Wu et al., 2015). Bone marrow cells may also replenish
the diminished CPC pool after a cardiac injury (Mouquet et al.,
2005; Barile et al., 2011).
Improvement of Endogenous Cardiac
Healing
It is clear that the heart has some capacity to regenerate through
various cell participants to support normal deterioration.
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FIGURE 1 | Endogenous cardiac regeneration. After a cardiac insult, a significant number of cardiac mycoytes die and vessel density gets reduced. In a very
limited way, the heart has the ability to regenerate but it is insufficient to compensate for the total damage. The cellular participants in the endogenous regeneration
process may include cardiac myocytes (pink cells, black lines), local cardiac progenitor cells (blue cells), and recruited peripheral stem cells (red cells). These cells have
the potential to proliferate and participate in the regeneration of cardiac myocytes, angiogenesis, and the release of trophic factors that may reduce cardiac cell death.
Modes of the cells participation are identified by colored arrows (peripheral stem cell, red; cardiac progenitor cell, blue; cardiac myocyte, green). Methods that could
be employed to improve these endogenous mechanisms include cell and/or gene therapy and pharmacologic treatments.
Unfortunately, it is evident that the potential is limited and
unable to compensate for the extent of damage that may occur
after a myocardial infarction. A number of approaches have been
attempted to improve cardiac regeneration, including cell and
gene therapy. Reasonable benefits have been determined from
these therapeutic approaches though the beneficial mechanisms
lie in the trophic factors produced or through the activation of
endogenous cardiac healing. Recently, it is has been identified
that common drugs administered to patients with cardiovascular
disease may alter endogenous stem cell populations. Profiting
from these interactions may be a potential manner to assist in
cardiac repair.
Cell Therapy
Attempts to repair the damaged myocardium with cardiac
myocytes or skeletal myocytes have shown limited potential.
A large amount of enthusiasm therefore has focused on the
potential that stem cells could have in cardiac regenerative
therapy. Many stem cell types have been examined including
embryonic stem cells, induced pluripotent stem cells, various
bone marrow stem cell types, and cardiac stem cells. Cell
therapy efforts have been reviewed more exhaustively elsewhere
(Goumans et al., 2014; Pavo et al., 2014).
Embryonic stem cells (ESC) and induced pluripotent stem
cells have a great power to differentiate into all cell types making
them an attractive choice for replacing lost myocardium. While
efforts have been made to program these stem cell types to reduce
tumor potential, it still remains a risk as well as a potential
immunological challenge in the recipient (Anderson et al., 2014;
De Almeida et al., 2014; Zhang et al., 2015). Cardiac myocytes
derived from human pluripotent stem cells were shown to be
anti-arrhythmic in a guinea pig model (Shiba et al., 2012).
However, in a large primate model, the transplantation of human
ESC derived cardiac myocytes was associated with ventricular
arrhythmias, although they were transient and did not induce
sudden death (Chong et al., 2014). As the human heart has a
significantly slower heart rate and larger size than the primate
model, the propensity of arrhythmias from ESC transplant
increases (Lalit et al., 2014). For this reason, the transplantation
of ESC derived cardiac myocytes needs to be tested with caution
in humans (Anderson et al., 2014).
Due to the issues that still remain with pluripotent stem cells,
adult stem cells could be a more plausible option for cell therapy.
Autologous adult stem cells can be delivered to patients reducing
any risk for immune complications. As these cell types have a
more differentiated lineage, no concerns for tumor formation
remain. In animal models, cardiac cell therapy with bone marrow
stem cells or cardiac stem cells can improve cardiac function,
decrease infarct size, improve myocardial regeneration, increase
vascular density, and activate endogenous stem cell populations
(Figure 2; Yoon et al., 2010; Loffredo et al., 2011; Dong et al.,
2012; Avolio et al., 2015). These benefits seem to translate into
similar results in a portion of human clinical trials. Individual
reports have described improved cardiac function, decreased scar
size, and improved physical capabilities, such as improvements
in the 6min walking distance test, after adult stem cell therapy
(Bolli et al., 2011; Malliaras et al., 2014b; Golpanian et al., 2015;
Mathiasen et al., 2015). However, results from the meta-analysis
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FIGURE 2 | Cardiac cell therapy. After a cardiac injury, a patient’s adult stem cells are isolated. These cells can be isolated from either cardiac tissue or from
peripheral sites. The cells are amplified to have a sufficient number for therapeutic transplant. The cells are injected into the patient either intravenously or intracardiac,
alone or in the presence of pro-survival cocktails, hydrogels, or extracellular matrix patches. The injected cells can participate themselves in cardiac regeneration or
improve endogenous healing by excreting paracrine factors which reduce apoptosis and increase stem cell recruitment and activity and angiogenesis to repair the
damaged cardiac tissue.
of cell based cardiac studies revealed no clinical benefit 3–12
months after cell therapy (Gyöngyösi et al., 2015).
The beneficial mechanism of adult stem cells has not been
direct differentiation to cardiac myocytes as originally hoped for.
Instead the more prominent mechanism appears to involve the
activation of endogenous healing pathways through paracrine
factors provided by the transplanted cells. These pathways
can reduce myocardial apoptosis, activate cardiac myocytes
proliferation and endogenous stem cell recruitment (Zhang et al.,
2007; Fischer et al., 2009; Malliaras et al., 2014a; Avolio et al.,
2015). Cell therapy also aids in improving vascular density in
the damaged myocardium either through direct differentiation
or activating endogenous angiogenesis. The importance of this
mechanism to cardiac repair was highlighted recently (Yoon
et al., 2010). In this study, infarcted mice were treated with
ganciclovir after MSC therapy to induce cytotoxicity in stem
cell derived endothelial cells. The death of the endothelial
cells and the subsequent decrease in vessel density led to a
significant deterioration of cardiac function. Even though cell
therapy approaches may not themselves replace the lost cardiac
myocytes, their release of trophic factors that reduce apoptosis or
recruit endogenous stem cells and their ability to aid in vascular
remodeling may provide a significant benefit to cardiac repair.
An additional point to note is that the retention of the
stem cells in the myocardium is extremely low, reducing their
potential therapeutic effects. The transplantation of sheets of cells
or in combination with hydrogels or patches improve the cell
engraftment rate, thus improving cardiac function (Ishii et al.,
2014; Roche et al., 2014; Tano et al., 2014; Zhang et al., 2015).
Interestingly, even altering the growth media of the cells can
improve their retention in the tissue (Kim et al., 2014). Pro-
survival cocktails can also be used to improve the duration and
number of the cells in the myocardium (Laflamme et al., 2007;
Gautam et al., 2015). Components of the pro-survival cocktails
include growth factors, anti-apoptotic molecules such as cell-
permeant Bcl-XL and caspase inhibitors, immunosuppressants,
and vasodilators.
Gene Therapy
Natural reparative signaling pathways occur in the heart after
a cardiac injury. However, these signals are usually transient,
not enduring long enough to support complete endogenous
repair (Askari et al., 2003; Schenk et al., 2007). As discussed in
the previous section, transplanted stem cells provide paracrine
factors that support natural tissue repair. Gene therapy is a
mechanism to capitalize on these natural factors to prolong
or reactivate the signals. Cardiac diseases gene therapy has
encompassed delivery options including adenovirus, direct
plasmid transfer, microbubbles and modified RNA.
Growth factors and chemokines are greatly implicated in
cardiac repair and their expression through gene therapy
techniques can improve cardiac function (Kanashiro-Takeuchi
et al., 2011). Beneficial mechanisms induced by this approach
include elevated proliferation, mobilization, and recruitment
of endogenous local and peripheral stem cell populations
(Figure 3). A number of growth factor or cytokine candidates
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FIGURE 3 | Cardiac gene therapy. In animal models, cardiac gene therapy has shown to be successful when delivered by direct plasmid, in a lenti- or adenovirus,
or in exosomes. Growth factors, chemokines, transcription factors and miRNAs have all been tested in cardiac gene therapy. Expression of these proteins and
miRNAs have the potential to improve endogenous cardiac regeneration through the recruitment, activation and differentiation of local and peripheral stem cells,
improved vascular density, or by proliferation of cardiac myocytes. Additional cardiac “rescuing” gene therapy targets (e.g., Serca2a) can improve cardiac function but
it has yet to been investigated if these approaches can alter endogenous cardiac regeneration.
have been demonstrated to be favorable in cardiac repair,
including, but not limited to, vascular endothelial growth factor,
monocyte chemotactic protein 3, and placental growth factor
(Schenk et al., 2007; Iwasaki et al., 2011; Zangi et al., 2013). In
particular, stromal derived factor-1 expression can recruit various
C-X-C chemokine receptor type 4 positive cell populations
including CPC, MSC and very small embryonic like stem cells
(Askari et al., 2003; Kucia et al., 2006; Dong et al., 2012). Stem cell
factor gene therapy has been described to induce cardiac myocyte
and CPC proliferation (Yaniz-Galende et al., 2012; Ishikawa
et al., 2015). Gene therapy by direct injection of growth factor
or chemokine plasmids, namely stromal derived factor-1 and
vascular endothelial growth factor, has been demonstrated in
patients with ischemic heart disease to be safe and show signs
of a functional benefit (Favaloro et al., 2013; Penn et al., 2013).
In particular, stromal derived factor-1 plasmid injection into
cardiac heart failure patients has shown functional therapeutic
promise by improving ventricular remodeling in patients with
more advanced cardiac dysfunction (Chung et al., 2015).
Transcription factors have also been targeted in cardiac gene
therapy. Hypoxia inducible factor 1-alpha has been an appealing
target as it is protective by regulating angiogenesis and survival,
as well as the expression of chemokines capable of recruiting stem
cells (Semenza, 2014). Plasmid or adenovirus transfer of hypoxia
inducible factor 1-alpha into the myocardium can improve
cardiac repair, decrease cardiacmyocyte apoptosis, mobilize bone
marrow stem cells to the heart, and activate c-kit+ cells in the
myocardium (Huang et al., 2011, 2014; Ong et al., 2014). In
vivo reprogramming of fibroblasts with the cardiac transcription
factors GATA4, Mef2c, and Tbx5 generates functional cardiac
myocytes which are fully incorporated in the myocardium and
decrease scar size, thus improving cardiac function (Inagawa
et al., 2012; Qian et al., 2012). An additional tested approach
is the manipulation directly of the proliferation of the cardiac
myocytes. Injection of an adenovirus expressing cardiac specific
telomerase or the Yes-associated protein can induce cardiac
myocyte proliferation and improve overall cardiac repair (Bär
et al., 2014; Lin et al., 2014).
MicroRNAs (miRNAs) have also been employed in gene
therapy techniques to promote cardiac regeneration. miRNAs
are small non-coding RNAs that bind mRNA and inhibit
translation. Eulalio et al. performed a high throughput screening
of miRNAs on neonatal rat cardiac myocytes to identify
candidates that induce proliferation (Eulalio et al., 2012).
They then demonstrated that in fact when an adenovirus
expressing either miR-590-3p or miR-199a was injected at
the time of myocardial infarction, they could induce cardiac
myocyte proliferation resulting in decreased infarct size and
improved cardiac function. Endogenous CPC proliferation was
elevated after lentiviral delivery of miR-17-92 (Sirish et al.,
2012). The in vivo reprogramming of cardiac fibroblasts to
cardiac myocytes by lentiviral transfer of a combination of
miRNAs (1, 133, 208, 499) has also been demonstrated to be a
successful approach to induce endogenous cardiac regeneration
(Jayawardena et al., 2015). miRNAs can also be a target of
inhibition. To combat the anti-angiogenic properties of miR-
92a, an antagomir was designed to inhibit the miRNA thus
increasing capillary density after myocardial infarction (Bonauer
et al., 2009). The potential of miRNAs in cardiac repair has
been reviewed more thoroughly elsewhere (Hodgkinson et al.,
2015).
Additional targets of cardiac gene therapy have included
calcium cycling proteins, extracellular matrix alterations,
adrenergic manipulation, and arrhythmias and have been
reviewed elsewhere (Nagai and Komuro, 2012; Scimia et al.,
2013). These approaches appear to have a sufficient effect on their
target and improve cardiac function but besides the mention that
targeting calcium cycling proteins can block cardiac remodeling,
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little is known on the effect of these strategies and the survival
or regeneration of the tissue (Katz et al., 2014). It would be
interesting to examine the cell proliferation or anti-apoptotic
effects of these therapies especially as atrial fibrillation and
changes in calcium channels and intracellular calcium changes
can alter cardiac myocyte and CPC proliferation (Ferreira-
Martins et al., 2009; Chernyavskaya et al., 2012; Gambini et al.,
2012; Demion et al., 2014).
Pharmacological Interventions
The common pharmaceutics given to patients who have had
a myocardial infarction include aspirin, beta blockers, ace
inhibitors, angiotensin receptor blockers, and statins. These
drugs aim at reducing blood clots, regulating blood pressure,
stabilizing electrical activity, and reducing cholesterol. These
approaches improve patient lifestyle and prolong life but
they do not replace the damaged tissue that is lost after a
myocardial infarction. However, evidence is mounting that these
drugs may actually have either positive or negative effects
on endogenous stem cell populations and cardiac myocyte
survival and proliferation (Table 1). Potential may exist in
refining current therapies to control their primary functions
and generate a balance in myocardial healing. These drug
regiments, as well as, patient’s age and pathophysiological state
likely have grave implications on endogenous stem cell activity
as well as exogenous cell therapy approaches. Increased age
and cardiovascular comorbidities have well been described
to impair endogenous cardiac repair (Gambini et al., 2012;
Lee and Poh, 2014; Hariharan and Sussman, 2015). Research
regarding the effects of these parameters has been limited in
animal studies. Awareness of these effects will allow clinicians
to anticipate potential adverse effects and facilitate maximal
results.
Aspirin
Aspirin can reduce the risk of myocardial infarction in
high-risk patients and prevent an additional event. However,
contradictions exist with aspirin including an increased risk of
gastrointestinal bleeding. Chronic treatment with aspirin may
inhibit the cardiac proteasome and reduce cardiac myocyte
viability (Tan et al., 2013). Interestingly, aspirin may have
negative effects on endogenous stem cell populations as well.
Aspirin can reduce EPC number and migration capacity (Boer
et al., 2011; Sato et al., 2013). Aspirin may also inhibit MSC
proliferation and induce apoptosis (Deng et al., 2009). No reports
have yet described the effects of aspirin on CPC but as non-
steroidal anti-inflammatory drugs can negatively affect ESC
cardiac differentiation, it could have an implication on in vivo
cardiac differentiation as well (Chillar et al., 2011). The negative
effects of aspirin on endogenous stem cells may be due to its
anti-inflammatory effects. Pro-inflammatory signals have been
demonstrated to aid in regulating and activating endogenous
stem cell populations (Reber et al., 2006; Mirantes et al., 2014).
Beta Blockers
After a myocardial infarction, an excessive number of
catecholamines are released. To reduce their deleterious action,
beta adrenergic receptor blocking agents are administered to
patients. These drugs aid in the prevention of additional infarcts
and reduce cardiac arrhythmias. The majority of the inotropic
effects of the beta adrenergic signaling pathway are mediated by
the beta 1 receptor (Bristow et al., 1986). This pathway as well
can promote cardiac myocytes apoptosis (Seqqat et al., 2012).
Conversely, beta 2 adrenergic receptor signaling is anti-apoptotic
and cardioprotective (Zhang et al., 2010). Interestingly, general
blockade of beta adrenergic receptor signaling by propanolol
in cardiac pressure overload actually induces cell cycle gene
TABLE 1 | Effects of common pharmaceuticals on cardiac myocytes and endogenous stem cells.
Aspirin Beta Blockers ACE
inhibitors/angiotensin
receptor blockers
Statins
Beta 1 Beta 2
Cardiac myocytes ↓ Viability
Tan et al., 2013
↓ Apoptosis
↓ Inotropy
Bristow et al., 1986;
Seqqat et al., 2012
↑ Apoptosis
↓ Cardioprotection
Zhang et al., 2010
↓ Apoptosis
Kajstura et al., 1997;
Xu et al., 2010
↓ Apoptosis
↑ Proliferation
Ito et al., 2004; Tang et al., 2011;
Zhang et al., 2012
Cardiac progenitor cells ? ↓ Apoptosis
Khan et al., 2013
↓ Proliferation
Ellison et al., 2007
↑ Number
↑ Proliferation
Suzuki et al., 2009; Gambini
et al., 2012
Peripheral stem cells ↓ Number
↓ Migration
↓ Proliferation
↑ Apoptosis
Deng et al., 2009; Boer
et al., 2011; Sato et al.,
2013
↑ Number
Sorrentino et al., 2011
? ↑/↓ Number (?)
↑/↓ Differentiation (?)
Thum et al., 2011;
Durik et al., 2012; Jung
et al., 2012; Li et al.,
2012; Wu et al., 2013;
Liu et al., 2015
↑ Number
↑ Mobilization
↑ Proliferation
↑ Survival
↑ Differentiation
Erbs et al., 2011; Shaw et al.,
2011; Cai et al., 2013; Cohen
et al., 2013
The common pharmaceuticals prescribed after a cardiac injury are detailed. The positive effects on cardiac myocytes, cardiac progenitor cells, or peripheral stem cells are highlighted
in blue and negative effects are highlighted in red. Blockade of the beta adrenergic signaling system has been divided by receptors beta 1 and beta 2.
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expression and increases the number of ki-67 proliferating
cardiac myocytes primarily through the beta 2 receptor pathway
(Musumeci et al., 2011).
Catecholamines can stimulate proliferation in endogenous
CPC through beta 2 adrenergic receptor signaling which is
the more highly expressed beta adrenergic receptor on these
cells (Ellison et al., 2007). Similarly to cardiac myocytes,
stimulation of beta 1 adrenergic receptor can induce CPC
apoptosis (Khan et al., 2013). Remarkably, a higher number
of isolated CPC has been associated with patients on beta
blocker therapy (Gambini et al., 2012). Beta adrenergic signaling
manipulationmay also alter peripheral stem cell activity. The beta
1 specific adrenergic receptor blocker, nebivolol, can increase
EPC number after myocardial infarction (Sorrentino et al.,
2011). Clenbuterol, a beta 2 receptor agonist, along with the
chemokine GCSF, augments peripheral blood CD34+ cells after
myocardial infarction (Tanaka et al., 2013). Research is scarce on
the beta adrenergic receptor signaling role in endogenous stem
cell differentiation. As activation of this pathway can improve
cardiac differentiation in ESC, it may be interesting in future
studies to examine CPC and peripheral stem cell differentiation
after manipulation of this pathway (Yan et al., 2011).
Clearly manipulation of the beta adrenergic receptor pathway
may improve endogenous cardiac regeneration. Stimulating the
beta 2 receptor could likely reduce cardiac myocytes apoptosis
and improve the local and peripheral endogenous stem cell
reservoir. It is likely that treatment with a beta 1 receptor specific
blocker and a beta 2 specific agonist may provide a balance in
cardiac therapy as recently demonstrated (Sun et al., 2014).
Angiotensin Converting Enzyme
Inhibitors/Angiotensin Receptor Blockers
The renin/angiotensin aldosterone system (RAAS) is altered in
cardiovascular diseases. In heart failure and after a myocardial
infarction, drugs (e.g., angiotensin converting enzyme inhibitors,
angiotensin receptor angatonists) which block this pathway are
recommended to relax blood vessels, thereby reducing blood
pressure (Mentz et al., 2013). These drugs may aid in reducing
apoptosis of cardiac myocytes as well. Angiotensin II signaling
can increase apoptosis of cardiac myocytes (Kajstura et al., 1997;
Xu et al., 2010). Conversely, the benefits of these drugs are
unclear for stem cells. For example, one report described that
the activation of angiotensin like-1 receptor after myocardial
infarction increased the accumulation of vascular stem cells,
while another article found instead that blockade of the signaling
increases the number of EPC (Jung et al., 2012; Li et al., 2012).
Opposing results also exist on the angiogenic properties of EPC
in the presence of RAAS signaling (Thum et al., 2011; Durik et al.,
2012). The RAAS may actually be beneficial for other stem cell
types; improving cardiac differentiation of ESC and MSC and
rendering MSC more apoptotic resistant and amplifying their
growth factor expression (Durik et al., 2012; Wu et al., 2013; Liu
et al., 2015). Little has been investigated on the RAAS and CPC.
The only article published to date identifies a specific angiotensin
1 receptor expressing CPC population that is senescent with
impaired growth and an increased susceptibility to apoptosis
(D’Amario et al., 2011). Overall, the use of drugs antagonizing the
RAAS are beneficial toward cardiac function and cardiacmyocyte
survival, but their use in stem cell mediated regeneration requires
a further, more detailed investigation.
Statins
Statins are cholesterol lowering drugs and have also been
associated with having anti-inflammatory and anti-thrombotic
effects (Angeli et al., 2012). Statin treatment has been described to
block apoptosis of cardiac myocytes and can elevate the number
of proliferating cardiac myocytes after a myocardial infarct (Ito
et al., 2004; Suzuki et al., 2009; Tang et al., 2011; Zhang et al.,
2012). Statins also have positive effects on endogenous stem
cell populations. Progenitor cells in the heart are elevated after
statin treatment and myocardial infarction (Suzuki et al., 2009).
The amplification potential of CPC is significantly higher from
patients on statins (Gambini et al., 2012). Bonemarrow stem cells
and EPC are also positively regulated by statins. Elevated number,
mobilization, proliferation, improved differentiation capacity,
and increases in survival have all been described in peripheral
stem cell populations after statin treatment (Erbs et al., 2011;
Shaw et al., 2011; Cai et al., 2013; Cohen et al., 2013). Taken all
together, statin therapy appears to enhance endogenous cardiac
repair pathways.
Additional Approaches
A few novel approaches have been described in recent years to
improve endogenous stem cell mediated cardiac regeneration.
A unique idea proposed was to find a method to trap the
circulating stem cells to the tissue where their action is required.
Baumer et al. generated a bi-functional fusion protein that
binds damaged vessels and CD133+ progenitor cells (Baumer
et al., 2012). They were able to demonstrate that this molecule
could improve progenitor cell adhesion thereby increasing
capillary density and improving cardiac function. Tetravalent
antibodies have also been employed for the same goal. These
antibodies were generated to target an epitope on apoptotic
cardiac myocytes, CD34, CD133, and c-kit cells (Malecki et al.,
2013). This approach significantly improved the recruitment and
retention of the various stem cell populations to the damaged
myocardium.
As described above, stem cell populations provide trophic
factors to the damaged myocardium. Due to this idea, exosomes
have been exploited as a possible means to improve cardiac
regeneration. In fact, ESC exosome delivery after a myocardial
infarct improved overall cardiac function, increased capillary
density and proliferating cardiac myocytes and CPC and
decreased cardiac myocyte apoptosis (Khan et al., 2015). This
suggests a unique strategy to improve endogenous cardiac repair.
Future studies will determine if exosomes from other stem cells
types, such as MSC which produce a large number of paracrine
signals, can enhance regeneration even more.
Prospects and Conclusions
In summary, the heart has some capacity to regenerate in
response to a large insult such as a myocardial infarct, though
this process needs to be amplified to repair the tissue. The
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endogenous regeneration requires an orchestrated participation
from various cell types including cardiac myocytes and local and
peripheral stem cells. It is naïve to think that only one cell type
can participate in this regenerative process andmay actually limit
therapeutic opportunities.
As discussed in this review, known pharmacological therapies
may alter endogenous cardiac regeneration. Future studies are
required to expand on this topic to identify treatments that
will strike a balance between the drug’s primary function and
ability to aid or inhibit cardiac regeneration. For example, it
may be beneficial to refine the treatments so that they target
only specific pathways. A good example of this is in the use
of beta blockers. Physicians could choose to treat patients with
a beta 1 specific adrenergic blocker, as opposed to a non-
specific beta blocker, in combination with a beta 2 specific
adrenergic agonist accommodating blockade of the deleterious
beta adrenergic signaling (beta 1) and amplifying regenerative
downstream effects (beta 2). Statins also appear to be candidates
that aid in endogenous cardiac regeneration. Further studies will
need to validate this and may identify the mechanisms in which
statins can alter endogenous cells, potentially leading to more
focused regenerative therapeutic targets. The inhibitory repair
effects of drugs such as aspirin may be taken into account in
determining a patient’s drug regimen.
Refining current pharmacological therapies to enhance
endogenous cardiac regeneration has economic and practical
benefits for treatment. These drugs are already in current use in
clinical practice. As well, generic, low-cost versions of these drugs
are available; statin treatment may cost as little as $4 dollars per
month (Lazar et al., 2011). Cell and gene therapy approaches are
much more expensive and still require approval from regulatory
agencies. The costs of preparation and processing of these drugs
under goodmanufacturing procedures is very high. The first gene
therapy drug on the market, although for a genetic disease, costs
more than $40,000 per vial (Burger and Hirschler, 2014). Clinical
administration and multiple treatments augment the price for
this type of therapy even more. However, if these therapies can
eventually to be proven to heal the heart, then the cost-benefit
may be worth the initial price.
To truly improve endogenous cardiac regeneration, the field
needs to open itself to the possibility that therapy includes more
participants. A multidimensional approach will likely ameliorate
the overall repair process, resulting in a more complete
regeneration. This is already evident in studies combining both
cell and gene therapy where a greater cardiac repair is reported
(Schenk et al., 2007; Huang et al., 2014; Ong et al., 2014).
One can foresee a multi-faceted treatment plan for patients
including pharmacological approaches and cell and gene therapy.
This perspective has the ability to translate into other fields
of regenerative medicine where endogenous healing may exist,
including the central nervous system, diabetes, or bone and
cartilage damage.
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